BIOCON - Biocon Ltd. Share Price

Pharmaceuticals & Biotechnology

₹352.65-4.60(-1.29%)

Market Closed as of Jun 17, 2025, 15:30 IST

What does Biocon Ltd. do?

Pharmaceuticals•Healthcare•Mid Cap

Biocon is a prominent pharmaceuticals company based in India, with the stock ticker BIOCON. The company boasts a market capitalization of Rs. 40,064 Crores.

Biocon Limited, along with its subsidiaries, specializes in the manufacture and sale of biotechnology products and research services across various markets including India, Brazil, Singapore, and beyond. The company operates through four key segments: Generics, Novel Biologics, Biosimilars, and Research Services.

In the Generics segment, Biocon provides a range of products such as generic formulations and Active Pharmaceutical Ingredients (API) which include anti-diabetics, immunosuppressants, and cancer therapies. The Novel Biologics arm focuses on innovative treatments, including molecules targeting head and neck cancer and psoriasis. Furthermore, the Biosimilars segment offers products like insulins, trastuzumab, pegfilgrastim, and bevacizumab.

Biocon also delivers integrated discovery, development, and manufacturing services to various sectors including pharmaceuticals, biotechnology, animal healthcare, consumer goods, and agrochemicals. Established in 1978, the company is headquartered in Bengaluru, India.

Over the last twelve months, Biocon recorded a revenue of Rs. 16,012.2 Crores and has exhibited impressive revenue growth of 99.7% over the past three years. The company is committed to returning value to its shareholders, offering a dividend yield of 0.52% annually, with a recent distribution of Rs. 2 per share.

Industry Group:Pharmaceuticals & Biotechnology

Employees:16,315

Website:www.biocon.com

Valuation
Market Cap	42.67 kCr
Price/Earnings (Trailing)	35.77
Price/Sales (Trailing)	2.66
EV/EBITDA	9.94
Price/Free Cashflow	31.26
MarketCap/EBT	24.79

Fundamentals
Revenue (TTM)	16.01 kCr
Rev. Growth (Yr)	-14.67%
Rev. Growth (Qtr)	6.44%
Earnings (TTM)	1.19 kCr
Earnings Growth (Yr)	-89.23%
Earnings Growth (Qtr)	199.26%

Profitability
Operating Margin	10.33%
EBT Margin	10.75%
Return on Equity	4.46%
Return on Assets	2.09%
Free Cashflow Yield	3.2%

Description	Share	Value
Biosimilars	54.4%	2.5 kCr
Generics	23.1%	1 kCr
Research Services	22.5%	1 kCr
Total		4.5 kCr

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Category	BIOCON	Pharmaceuticals
PE	35.77	37.97
PS	2.66	5.34
Growth	2.7 %	7.2 %

Summary of Latest Earnings Report from Biocon

Summary of Biocon's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated: Feb 25

Outlook and Major Points from Biocon Management:

1. Growth Transition and Visibility:
Management maintains a positive outlook, expecting a transition to growth in the second half of FY25 and into FY26. Improved visibility across all businesses is driven by regulatory clearances, new product launches, and operational execution.

2. Biosimilars Business:

Strong Momentum: Sustained double-digit growth (14% YoY) in Q3, with key products like Ogivri (Trastuzumab) and Fulphila (Pegfilgrastim) gaining market share in the U.S. (22% and 23% shares, respectively).
Upcoming Launches: Ustekinumab (Stelara biosimilar) to launch in the U.S., EU, and Japan in Q4 FY25. Bevacizumab and Aspart approvals in the U.S. expected post-FDA site clearances. Denosumab BLA filed in the U.S.
Margins: Core EBITDA margins at 22-23%, supported by cost optimization and vertical integration.

3. Generics Business:

Recovery Drivers: Sequential growth (10% QoQ) expected to continue with Liraglutide (GLP-1 generic) launches in the U.K./EU (Q4 FY25) and the U.S. (mid-2025). Semaglutide (GLP-1) development completed; filings in key markets targeted for 2026.
Operational Wins: U.S. FDA cleared Bengaluru API sites; Cranbury facility qualified for statin production.

4. Research Services (Syngene):

Return to Growth: 11% YoY revenue growth in Q3, with broad-based recovery across divisions. EBITDA margin improved to 31%.
Outlook: Stabilizing U.S. biotech demand and China+1 strategy driving contract conversions for long-term growth.

5. Financial Highlights:

Group Revenue: INR 3,821 crore (10% YoY growth, ex-divestments).
Core EBITDA: INR 1,007 crore (26% margin), with debt management prioritized post-Viatris milestone closures.

6. Strategic Focus:

Regulatory Milestones: FDA VAI status for key manufacturing sites paves the way for critical approvals.
Debt Management: Focus on deleveraging while funding growth.

Key Catalysts: New biosimilar launches (Stelara, Bevacizumab, Aspart), Liraglutide/Semaglutide rollouts, and Syngene's margin expansion.

Q&A Session

Last updated: Feb 25

Question 1 (Damayanti Kerai - HSBC):
What is the potential uptake expectation for biosimilar Ustekinumab (Stelara) in the U.S., considering it is a Part D product and dynamics similar to Humira biosimilars?

Answer:
Biocon anticipates strong global uptake for Ustekinumab, leveraging competitive positioning and lessons from prior biosimilar launches. The U.S. team emphasized strategic customer engagement and confidence in immunology portfolio synergies. Margins remain stable despite forex impacts, with growth driven by volume, not low-margin channels.

Question 2 (Neha Manpuria - BofA):
What is Biocon's diluted stake in Biocon Biologics (BBL) post the 1.5% stake purchase, and how is net debt impacted? What drives Generics' recovery?

Answer:
Biocon's stake in BBL increased to ~72%. Net debt rose to ~USD 1.3B due to bridge loans. Generics growth will stem from Liraglutide launches in EU/U.K. (Q4 FY25) and the U.S. (mid-CY25), alongside API volume recovery and new U.S. product launches, targeting mid-teens growth in FY26.

Question 3 (Shyam Srinivasan - Goldman Sachs):
Why don't biosimilar revenue growth rates align with market share gains? How is capital allocation balancing debt and subsidiary stakes?

Answer:
Revenue-growth vs. market-share disparity reflects expected price erosion and divested India Branded Formulations' impact. Debt management prioritizes growth investments (e.g., facility clearances, product launches), with Syngene stake maintained at ~52%. BBL's IPO remains a debt-reduction lever.

Question 4 (Amey Chalke - JM Financial):
What is Biocon's status on Semaglutide (Sema) development, and how will insulin capacity expansion aid growth?

Answer:
Sema development is progressing, with U.S. DMF filings, bioequivalence studies, and planned FY26 submissions. Insulin drug-product capacity will double by Q1 FY26, supporting global demand. Biocon aims to be a top insulin player, leveraging vertical integration and device strategies.

Question 5 (Love Sharma - JP Morgan):
How are investor liquidity options tied to BBL's IPO being managed, and how was the Viatris settlement funded?

Answer:
Biocon is aligning with investors via ongoing discussions, with an IPO remaining a key option. The USD 160M Viatris milestone payment was settled using existing liquidity and receivables adjustments, closing all deferred obligations.

Question 6 (Surya Patra - Phillip Capital):
How prepared is Biocon for Ustekinumab's launch, and what is Denosumab's timeline? How critical are China's Tacrolimus approval and the Cranbury facility?

Answer:
Ustekinumab's U.S. launch preparations include pre-negotiated contracts and Part D strategies. Denosumab's filings are underway globally, targeting 2026 launches. Tacrolimus in China and the Cranbury facility enhance market access and U.S. government contract eligibility, respectively.

Question 7 (Vivek Agrawal - Citi):
Are biosimilar margins conservative given new launches, and what are Semaglutide's approval timelines?

Answer:
Margins (22-23%) reflect R&D investments but may improve with high-value launches like Ustekinumab. Semaglutide approvals in Canada, Brazil, and India are expected from late 2026, with U.S./EU filings progressing.

Question 8 (Nitin Agarwal - DAM Capital):
What is Biosimilars' geographic revenue split, and how will insulin compete amid GLP-1 focus?

Answer:
Revenue splits: ~40% North America, ~35% Europe/Japan/Australia, ~25% emerging markets. Insulin demand remains robust despite GLP-1 buzz, with Biocon's integrated capacity and device strategy securing long-term competitiveness.

Question 9 (Bharat Seth - Quest):
What is Biosimilars' long-term growth outlook, and how will Generics improve margins?

Answer:
Biosimilars aim for 75%+ CAGR (FY23-FY28) via 5 U.S. and 3 global launches. Generics' margin recovery (10-14%) hinges on Liraglutide/Semaglutide launches, cost optimization, and Vizag facility utilization.

Question 10 (Alankar Garude - Kotak):
How will R&D spends trend, and what is the Vizag facility's role?

Answer:
R&D (7-9% of revenue) will fluctuate with clinical trial phases. Vizag diversifies API production, serving captive and external customers, with new immunosuppressant products enhancing utilization.

Shareholder Name	Holding %
KIRAN MAZUMDAR SHAW	40.36%
GLENTEC INTERNATIONAL	19.76%
LICI ULIP-GROWTH FUND	5.34%
SBI HEALTHCARE OPPORTUNITIES FUND	3.43%
KOTAK EQUITY OPPORTUNITIES FUND	1.28%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA VIS	1.25%
ARUN SURESH CHANDAVARKAR	1.1%
Others	0.46%
RAVI RASENDRA MAZUMDAR	0.44%
DEV MAZUMDAR	0.08%

Balance Sheet for Biocon

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	14.9%	140	122	90	197	125	111
Current investments	-56.5%	28	63	326	321	1,512	262
Loans, current	-	0	0	0	0	22	22
Total current financial assets	-37.9%	1,213	1,952	1,952	1,885	2,958	1,806
Inventories	19.1%	792	665	773	560	606	542
Total current assets	-21%	2,181	2,760	2,882	2,566	3,635	2,402
Property, plant and equipment	17.2%	991	846	838	842	779	747
Capital work-in-progress	6.2%	579	545	464	329	300	270
Investment property	-3.5%	56	58	60	62	64	66
Goodwill	-	38	0	0	0	0	0
Non-current investments	8.4%	10,038	9,256	9,144	8,950	4,839	5,018
Loans, non-current	-	0	0	0	0	0	19
Total non-current financial assets	6.9%	10,062	9,410	9,293	9,093	4,970	5,159
Total non-current assets	8.9%	11,990	11,008	10,801	10,464	6,260	6,467
Total assets	2.9%	14,170	13,768	13,682	13,030	9,896	8,869
Borrowings, non-current	4.4%	2,131	2,041	1,919	1,298	204	76
Total non-current financial liabilities	4.4%	2,154	2,064	1,936	1,318	223	90
Provisions, non-current	14.8%	32	28	28	25	24	26
Total non-current liabilities	4.6%	2,264	2,165	2,030	1,416	317	185
Borrowings, current	-	52	0	0	0	0	0
Total current financial liabilities	58.9%	837	527	641	543	420	450
Provisions, current	9.7%	35	32	30	28	27	25
Current tax liabilities	1%	102	101	100	97	94	91
Total current liabilities	47.1%	1,016	691	800	698	560	591
Total liabilities	14.9%	3,280	2,856	2,830	2,114	878	776
Equity share capital	0%	600	600	600	600	600	600
Total equity	-0.2%	10,890	10,912	10,852	10,916	9,018	8,093
Total equity and liabilities	2.9%	14,170	13,768	13,682	13,030	9,896	8,869

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022	Mar-2022
Cash and cash equivalents	36.8%	1,688	1,234	644	1,324	751	663
Current investments	76.2%	556	316	1,797	1,326	2,500	1,218
Loans, current	-	0	0	0	0	0	67
Total current financial assets	-1.4%	9,384	9,520	8,118	7,502	6,587	5,663
Inventories	0.4%	4,965	4,944	4,911	4,244	2,982	2,298
Total current assets	-0.2%	15,154	15,179	14,070	12,334	10,048	8,382
Property, plant and equipment	0.6%	7,462	7,418	7,662	7,535	7,171	5,677
Capital work-in-progress	9.3%	4,354	3,985	3,260	2,588	2,275	3,420
Goodwill	0.6%	16,467	16,372	16,334	16,136	26	26
Non-current investments	83.3%	1,253	684	243	604	256	362
Total non-current financial assets	46.2%	1,602	1,096	1,654	1,833	548	554
Total non-current assets	2.6%	41,974	40,892	40,507	39,709	12,616	12,012
Total assets	1.9%	57,128	56,071	54,577	52,043	22,664	20,394
Borrowings, non-current	-7.3%	11,982	12,932	15,007	15,290	4,438	3,998
Total non-current financial liabilities	-5.6%	13,678	14,497	19,106	20,145	6,208	5,737
Provisions, non-current	-5.1%	226	238	105	226	98	92
Total non-current liabilities	-5.4%	14,603	15,437	19,933	21,043	7,699	7,096
Borrowings, current	49%	4,168	2,797	2,816	2,480	1,178	906
Total current financial liabilities	5.2%	14,855	14,126	9,383	7,028	3,328	2,911
Provisions, current	15.6%	208	180	169	149	146	130
Current tax liabilities	-3.3%	268	277	236	225	230	162
Total current liabilities	2.9%	15,805	15,359	10,366	8,511	4,125	3,828
Total liabilities	-1.3%	30,408	30,796	30,300	29,554	11,824	10,924
Equity share capital	0%	600	600	600	600	600	600
Non controlling interest	4.3%	5,727	5,491	5,295	4,622	1,212	1,038
Total equity	5.7%	26,720	25,275	24,277	22,489	10,840	9,470
Total equity and liabilities	1.9%	57,128	56,071	54,577	52,043	22,664	20,394

Investor Care
Dividend Yield	0.52%
Dividend/Share (TTM)	2
Shares Dilution (1Y)	0.00%
Diluted EPS (TTM)	6.72

Financial Health
Current Ratio	0.96
Debt/Equity	0.6
Debt/Cashflow	0.18

Income Statement for Biocon

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	7.3%	563	525	511	533	563	519
Other Income	-13.7%	64	74	42	39	48	70
Total Income	4.7%	627	599	552	572	611	588
Cost of Materials	5.3%	277	263	223	218	264	292
Purchases of stock-in-trade	-	0	0	0	0	0.2	0.3
Employee Expense	5.6%	132	125	120	117	118	112
Finance costs	8.5%	65	60	55	40	56	55
Depreciation and Amortization	13.8%	34	30	30	30	31	31
Other expenses	8.9%	136	125	132	114	125	123
Total Expenses	9.2%	631	578	551	550	578	537
Profit Before exceptional items and Tax	-123%	-3.6	21	1.1	22	33	51
Exceptional items before tax	-	608	0	0	0	0	-5.2
Total profit before tax	2915%	604	21	1.1	22	33	46
Current tax	196.1%	8.4	-6.7	2.4	-9.3	12	11
Deferred tax	-52.2%	12	24	-2.2	17	-3.4	0
Total tax	11.8%	20	18	0.2	7.8	8.9	11
Total profit (loss) for period	26400%	584	3.2	0.9	14	24	35
Other comp. income net of taxes	-1414.3%	-8.2	1.7	-2.3	1.1	-2.7	-2.8
Total Comprehensive Income	14643.6%	576	4.9	-1.4	15	21	32
Earnings Per Share, Basic	500%	4.88	0.03	0.01	0.12	0.2	0.29
Earnings Per Share, Diluted	499%	4.87	0.03	0.01	0.12	0.2	0.29

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	6.7%	2,127	1,993	1,738	2,028	1,988	2,885
Other Income	-28.9%	193	271	187	150	202	118
Total Income	2.5%	2,320	2,264	1,925	2,179	2,190	3,002
Cost of Materials	5.5%	1,033	979	912	761	858	1,278
Purchases of stock-in-trade	-145.5%	0.5	2.1	1.7	0.9	0.9	125
Employee Expense	4.2%	452	434	368	390	345	510
Finance costs	187%	199	70	0.4	0.4	1.2	2.6
Depreciation and Amortization	3.4%	121	117	108	104	98	147
Other expenses	-13.3%	478	551	501	527	530	732
Total Expenses	1.3%	2,184	2,156	1,786	1,820	1,802	2,649
Profit Before exceptional items and Tax	26.2%	136	108	140	359	388	353
Exceptional items before tax	-99.5%	14	2,863	0	0	160	199
Total profit before tax	-95%	150	2,971	140	359	548	552
Current tax	-88.5%	15	123	54	78	112	59
Deferred tax	-	16	0	0	0	0	0
Total tax	-75.4%	31	123	54	78	112	59
Total profit (loss) for period	-95.9%	119	2,848	86	280	441	493
Other comp. income net of taxes	-1600%	-0.7	0.9	8	2.4	-7.7	13
Total Comprehensive Income	-95.9%	119	2,849	94	283	433	506
Earnings Per Share, Basic	-100%	1	23.87	0.72	2.36	3.72	4.165
Earnings Per Share, Diluted	-100%	1	23.82	0.72	2.34	3.71	4.135

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023	Sep-2023
Revenue From Operations	6.4%	3,821	3,590	3,433	3,917	3,954	3,462
Other Income	9.7%	35	32	1,134	49	566	158
Total Income	6.4%	3,856	3,623	4,567	3,966	4,519	3,620
Cost of Materials	28.2%	1,293	1,009	860	1,478	1,402	1,166
Purchases of stock-in-trade	77.1%	86	49	408	-0.1	33	372
Employee Expense	-0.3%	788	790	755	742	721	622
Finance costs	-1.3%	223	226	236	227	267	248
Depreciation and Amortization	1.2%	425	420	405	407	414	389
Other expenses	-1.2%	922	933	874	930	1,074	971
Total Expenses	4.7%	3,718	3,550	3,454	3,635	3,708	3,358
Profit Before exceptional items and Tax	93%	138	72	1,114	330	811	262
Exceptional items before tax	-32%	18	26	32	-8.8	21	-24
Total profit before tax	59.8%	156	98	1,146	322	832	238
Current tax	391.3%	114	24	225	136	83	52
Deferred tax	-186.5%	-38.8	47	58	-39.8	-27.8	-10.7
Total tax	5.7%	75	71	284	96	55	42
Total profit (loss) for period	207.7%	81	27	862	223	753	173
Other comp. income net of taxes	-89.3%	57	522	42	-17.2	43	190
Total Comprehensive Income	-75%	138	549	903	206	796	363
Earnings Per Share, Basic	30.1%	0.21	-0.13	5.51	1.13	5.52	1.05
Earnings Per Share, Diluted	30.1%	0.21	-0.13	5.51	1.13	5.51	1.05

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020	Mar-2019
Revenue From Operations	32.1%	14,756	11,174	8,184	7,106	6,367	5,514
Other Income	130.7%	866	376	213	254	161	144
Total Income	35.2%	15,621	11,550	8,397	7,360	6,529	5,659
Cost of Materials	59%	5,072	3,191	2,814	2,430	2,168	1,980
Purchases of stock-in-trade	9.1%	683	626	161	68	85	127
Employee Expense	22.2%	2,664	2,181	1,880	1,741	1,459	1,165
Finance costs	132.8%	974	419	68	58	65	71
Depreciation and Amortization	41%	1,569	1,113	814	715	552	448
Other expenses	38.2%	3,895	2,818	1,615	1,504	1,253	1,059
Total Expenses	37.3%	14,000	10,195	7,096	6,226	5,381	4,639
Profit Before exceptional items and Tax	19.6%	1,621	1,356	1,301	1,134	1,147	1,019
Exceptional items before tax	95.7%	-11.6	-291.4	-111.1	13	68	195
Total profit before tax	51.3%	1,609	1,064	1,190	1,147	1,215	1,214
Current tax	23.7%	314	254	212	222	315	204
Deferred tax	-	-86.9	0	0	0	0	8.5
Total tax	-10.7%	227	254	212	222	315	212
Total profit (loss) for period	102%	1,298	643	772	846	871	1,003
Other comp. income net of taxes	407.9%	387	77	110	214	-188.4	-72.4
Total Comprehensive Income	134.1%	1,684	720	882	1,061	682	930
Earnings Per Share, Basic	162.2%	8.55	3.88	5.44	6.24	6.32	7.65
Earnings Per Share, Diluted	162.7%	8.54	3.87	5.42	6.19	6.3	7.6

Cash Flow for Biocon

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	187%	199	70	0.4
Change in inventories	-438.8%	-104.6	-18.6	-110.6
Depreciation	3.4%	121	117	108
Unrealised forex losses/gains	154.5%	4	-4.5	-4.5
Adjustments for interest income	-102.9%	0	35	42
Share-based payments	-61%	17	42	30
Net Cashflows from Operations	-101.2%	-2.6	310	76
Dividends received	43.8%	-27.4	-49.5	0
Interest received	-	-65.7	0	0
Income taxes paid (refund)	-32.5%	28	41	28
Net Cashflows From Operating Activities	-157%	-123.2	219	48
Cashflows used in obtaining control of subsidiaries	-100%	0	4,071	0
Proceeds from sales of PPE	-81.2%	1.3	2.6	2.1
Purchase of property, plant and equipment	15.3%	302	262	239
Purchase of investment property	-	0	0	1,106
Purchase of intangible assets	10.3%	5.3	4.9	7.5
Cash receipts from repayment of advances and loans made to other parties	-104.8%	0	22	3
Dividends received	-46.9%	27	50	0
Interest received	-8.9%	42	46	28
Other inflows (outflows) of cash	249.2%	563	-375.8	1,110
Net Cashflows From Investing Activities	74.8%	-296.4	-1,177.8	-305.6
Payments to acquire or redeem entity's shares	-101.6%	0	65	0.3
Proceeds from exercise of stock options	3.4%	31	30	43
Proceeds from issuing debt	-100.1%	0	1,070	0
Proceeds from borrowings	-81%	500	2,632	73
Repayments of borrowings	-100%	0	2,515	0.7
Payments of lease liabilities	-	1.3	0	0
Dividends paid	203.4%	180	60	0
Interest paid	-90.6%	5.7	51	1.4
Net Cashflows from Financing Activities	-67%	344	1,039	112
Effect of exchange rate on cash eq.	-81.1%	1.7	4.7	3.5
Net change in cash and cash eq.	-188.6%	-74.3	86	-142.5

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2024	Mar-2023	Mar-2022
Finance costs	132.8%	974	419	68
Change in inventories	-200.3%	-886.4	886	-414
Depreciation	41%	1,569	1,113	814
Unrealised forex losses/gains	-210.8%	-105.4	97	8.6
Adjustments for interest income	-100.9%	0	112	112
Share-based payments	-27%	101	138	126
Net Cashflows from Operations	63.8%	3,408	2,081	1,439
Interest received	-	-161.3	0	0
Income taxes paid (refund)	27.6%	292	229	262
Net Cashflows From Operating Activities	59.5%	2,954	1,852	1,177
Cashflows used in obtaining control of subsidiaries	-	553	0	0
Proceeds from sales of PPE	947.6%	23	3.1	2.1
Purchase of property, plant and equipment	5.3%	1,680	1,596	1,698
Proceeds from sales of investment property	-	0	0	4,646
Purchase of investment property	-	0	0	4,302
Purchase of intangible assets	93.8%	251	130	227
Purchase of other long-term assets	-100%	0	15,664	0
Interest received	18%	145	123	60
Other inflows (outflows) of cash	381.5%	1,312	-464.8	-112.2
Net Cashflows From Investing Activities	93%	-1,004.5	-14,281.8	-1,699.1
Proceeds from issuing shares	-100.1%	0	1,237	0
Payments to acquire or redeem entity's shares	-101.6%	0	65	0.3
Proceeds from exercise of stock options	3.4%	31	30	43
Proceeds from issuing debt	-	800	0	0
Proceeds from borrowings	-94.4%	697	12,444	1,070
Repayments of borrowings	10148.1%	2,768	28	1,095
Payments of lease liabilities	-	42	0	0
Dividends paid	184.5%	203	72	-346.1
Interest paid	74.4%	847	486	110
Net Cashflows from Financing Activities	-117.9%	-2,332.7	13,049	242
Effect of exchange rate on cash eq.	-91%	2.9	22	3.3
Net change in cash and cash eq.	-159.6%	-380.4	641	-277.1

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical IndustriesPharmaceuticals	4.05 LCr	53.56 kCr	-4.71%	+9.04%	35.31	7.56	+10.28%	+28.38%
DIVISLAB	Divi's LabPharmaceuticals	1.77 LCr	9.42 kCr	+4.12%	+42.48%	85.63	18.78	+20.50%	+49.46%
CIPLA	CiplaPharmaceuticals	1.22 LCr	27.8 kCr	+0.14%	+2.61%	24.38	4.37	+7.01%	+33.22%
DRREDDY	Dr. Reddy's LabPharmaceuticals	1.14 LCr	32.07 kCr	+7.17%	+8.38%	20.87	3.55	+14.31%	+4.21%
LUPIN	LupinPharmaceuticals	88.48 kCr	22.19 kCr	-6.30%	+20.82%	30.59	3.99	+13.18%	+59.81%
AUROPHARMA	Aurobindo PharmaPharmaceuticals	64.49 kCr	31.57 kCr	-7.57%	-11.81%	18.49	2.04	+10.80%	+26.04%

BIOCON - Biocon Ltd. Share Price

What does Biocon Ltd. do?

Valuation

Fundamentals

Profitability

Revenue Breakdown

Sector Comparison: BIOCON vs Pharmaceuticals & Biotechnology

Comparative Metrics

Performance Comparison

Summary of Latest Earnings Report from Biocon

Latest News and Updates from Biocon

The Bad News

The Good News

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

Balance Sheet for Biocon

Investor Care

Financial Health

Updates from Biocon

Income Statement for Biocon

Cash Flow for Biocon

Is Biocon Better than it's peers?